Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03709550CT.gov Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | — | Withdrawn | — | — | — |
NCT03751436CT.gov Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02532114CT.gov Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT02228265CT.gov Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hypogonadism
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Enzalutamide (this asset) | Roswell Park Cancer Institute | P1/2 | B · 60 |
| Carboplatin | University of Washington | P2 | BB |
| Testosterone Undecylate | Royal College of Surgeons, Ireland | P3 | BB |
| Prednisone | SWOG Cancer Research Network | P3 | BB |
| Docetaxel | SWOG Cancer Research Network | P3 | BB |
| Abiraterone | SWOG Cancer Research Network | P3 | BB |
| Semaglutide | University Medical Centre Ljubljana | P3 | BB |
| Pembrolizumab | University of California, San Francisco | P2 | B |
| Bicalutamide | SWOG Cancer Research Network | P3 | B |
+27 more in the Hypogonadism cohort
Other indications for Enzalutamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P4 | BBB · 73 |
| Prostate Carcinoma | — | P4 | BBB · 73 |
| Breast Carcinoma | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Enzalutamide in Hypogonadism. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/enzalutamide-hypogonadism
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →